C > U mutations generate immunogenic peptides in SARS-CoV-2 @natcomms.nature.com @matemanc.bsky.social
@csabapallab.bsky.social
www.nature.com/articles/s41...
@csabapallab.bsky.social
Csaba Pal Lab's interest includes antibiotic resistance research, systems biology, and microbial experimental evolution. Account run by lab members. Szeged, Hungary http://group.szbk.u-szeged.hu/sysbiol/pal-csaba-lab-index.html
C > U mutations generate immunogenic peptides in SARS-CoV-2 @natcomms.nature.com @matemanc.bsky.social
@csabapallab.bsky.social
www.nature.com/articles/s41...
C > U mutations generate immunogenic peptides in SARS-CoV-2
APOBEC enzymesβkey players of the innate immune systemβinduce mutations that become fixed in viral genomes and enhance immune recognition.
nature.com/articles/s41...
#COVID_19 #Immunology #virus #infectiousdiseases #vaccine #Genetics
A dual-target antibiotic strategy, combining membrane disruption with another cellular pathway, shows promise in reducing bacterial resistance, offering a new direction in combating antimicrobial resistance. doi.org/g855sh
03.03.2025 17:02 β π 6 π 4 π¬ 0 π 0We are looking for a postdoc in #EvolutionarySystemsBiology.
Exciting science, amazing team, wonderful city!
landrylab.ibis.ulaval.ca/research-opp...
#evolution #synbio #systemsbiology #genomics
For previous research on #FutureAntibiotics and resistance development see our recent publications here: tinyurl.com/2cbyrx55 and tinyurl.com/2mxaz5a6 #MEvoSky
24.02.2025 11:09 β π 3 π 0 π¬ 0 π 05/5 - Contributors:
This work was spearheaded by @m-elvin.bsky.social and @marczikkely.bsky.social at HUN-REN Biological Research Centre, Szeged
4/5 - Implications for the Future:
These insights provide a blueprint for developing next-gen antibiotics ( #FutureAntibiotics) designed to stay one step ahead of bacterial defenses. Itβs a promising direction in the fight against #AntibioticResistance #AMR.
3/5 - A stark contrast:
Dual-target topoisomerase antibiotics, despite having two intracellular targets, were more prone to resistance. This highlights that which targets matter just as much as how many. #DrugDevelopment
2/5 β Dual target permeabilizers:
We tested three promising #DrugCandidates β POL7306, Tridecaptin M152-P3, and SCH79797 β against tough #ESKAPE pathogens like E. coli, K. pneumoniae, A. baumannii, and P. aeruginosa. The results? #ResistanceEvolution was significantly limited.
1/5 - The strategy:
By combining membrane disruption with another key cellular pathway, we can dramatically limit bacterial #resistance. This βdouble whammyβ makes it much harder for bacteria to fight back. #RationalDesign #Antibiotics
π¨ Our latest research in @naturecomms.bsky.social shows a promising strategy for less resistance-prone #antibiotics. For details, see the thread below and read the paper βExploring the principles behind antibiotics with limited resistanceβ here: #MEvoSky www.nature.com/articles/s41...
24.02.2025 11:09 β π 38 π 15 π¬ 1 π 2Two recent studies led by ππΊ @csabapallab.bsky.social find that resistance can develop against new π antibiotics even before they are widely used, compromising their effectiveness from the start. #antibioticresistance #AMR
03.02.2025 11:30 β π 1 π 1 π¬ 0 π 0Alternative drug modalities/approaches are desperately needed to supplement the pipeline of antibiotics.
27.01.2025 21:00 β π 5 π 3 π¬ 1 π 0ESKAPE pathogens are outsmarting us. Our latest paper in @naturemicrobiol.bsky.social reveals alarming ease of resistance evolution to antibiotics in development. Collaborative work with @csabapallab.bsky.socialβ¬
and Kintses Lab
ππ¦ OUT NOW - comprehensive analysis of the propensity of ESKAPE pathogens to evolve resistance to new and in development antibiotics by Csaba Pal, Balint Kintses, Balazs Papp and colleagues. Dive in here...
www.nature.com/articles/s41...
For a similar study on Gram-positive bacteria, check out our previous thread: bsky.app/profile/csab...
13.01.2025 16:30 β π 4 π 1 π¬ 0 π 07/7 π This study spearheaded by @lejladaruka.bsky.social, @marczikkely.bsky.social, @petraszili.bsky.social and @zoltanfarkas81.bsky.social at Biological Research Centre, Szeged. Important contributions from our long-term collaborators @balazs-papp-lab.bsky.social and Balint Kintses Lab.
13.01.2025 16:30 β π 2 π 0 π¬ 1 π 06/7 π’ Stay tuned! Our upcoming study will reveal a promising strategy to develop less resistance-prone antibiotics! #DrugDevelopment
13.01.2025 16:30 β π 1 π 0 π¬ 1 π 05/7 π¬ The study suggests that certain bacteria were less prone to develop resistance against some of the tested antibiotics, highlighting the potential in narrow-spectrum therapeutics. This presents hope for more effective future treatments. #Antibiotics #PublicHealth
13.01.2025 16:30 β π 1 π 0 π¬ 1 π 04/7 π Functional metagenomics revealed that mobile resistance genes exist not only in clinical isolates but also in the soil and even the human gut microbiome. Resistance is EVERYWHERE, making it harder to tackle with new treatments. #GlobalHealth
13.01.2025 16:30 β π 2 π 0 π¬ 1 π 03/7 𧬠Even more worrying: resistance mutations were already present in natural bacterial populations. This means that some bacteria may already have the arsenal to resist future antibiotics they have never encountered. #EvolutionOfResistance
13.01.2025 16:30 β π 1 π 0 π¬ 1 π 02/7 π¦ We tested 13 new antibiotics (some on the market for a couple of years, others still in development) against 4 of the most critical Gram-negative pathogens. The result? Resistance emerged in just 60 days. This shows how quickly bacteria can adapt! #AntibioticResistance
13.01.2025 16:30 β π 1 π 0 π¬ 1 π 01/7 The rise of drug-resistant infections is a global crisis, but many pharma companies have abandoned antibiotic R&D. While some new drugs are in development, our study shows resistance is emerging rapidly, even to these #FutureAntibiotics. Letβs unpack the results.β¬οΈ
13.01.2025 16:30 β π 2 π 0 π¬ 1 π 0π¨ Excited to share that our new study, βESKAPE pathogens rapidly develop resistance against antibiotics in development in vitroβ is published in @naturemicrobiol.bsky.social. For details, see the π§΅below and read the paper here: www.nature.com/articles/s41...
13.01.2025 16:30 β π 38 π 17 π¬ 1 π 3Awesome! Many thanks βͺ@thealexknapp.bsky.socialβ¬ for spotlighting our recent work!
13.01.2025 12:35 β π 2 π 0 π¬ 0 π 0Thrilled to share our latest work, "Antibiotic candidates for Gram-positive bacterial infections induce multidrug resistance" in Science Translational Medicine! For details, see the thread below and read the paper here: www.science.org/doi/10.1126/...
13.01.2025 11:52 β π 19 π 10 π¬ 1 π 2This work was spearheaded by Ana Martins, Fanni Judak and @zoltanfarkas81.bsky.social at Biological Research Centre, Szeged. Stay tuned for upcoming updates on #FutureAntibiotics - some exciting stuff on the horizon.
13.01.2025 11:52 β π 0 π 0 π¬ 0 π 0Based on our findings, early drug development must prioritize understanding resistance evolution at early stages. Additionally, R&D should focus on creating drug compounds with truly novel designs that actively minimize resistance development. 6/6
13.01.2025 11:52 β π 0 π 0 π¬ 1 π 0Key lab-observed resistance mutations already exist in natural bacterial populations. Decades of traditional antibiotic use might have selected for these variants, undermining the long-term efficacy of new drugs even before market introduction. #DrugDevelopment 5/n
13.01.2025 11:52 β π 0 π 0 π¬ 1 π 0We discovered overlapping resistance mechanisms: mutations in regulatory systems linked teixobactin resistance to patterns seen with vancomycin and daptomycin. This underscores the interconnected evolution of resistance, complicating efforts to combat #AMR. 4/n
13.01.2025 11:52 β π 1 π 0 π¬ 1 π 0